Table 2.
Item
|
Total (n = 93)
|
Do you prescribe therapeutic AC in case of detected thrombosis in one (or more) of the splanchnic veins? | |
Always | 23 (25) |
Usually | 48 (52) |
Sometimes | 21 (23) |
Never | 1 (1) |
Do you prescribe therapeutic AC in case of detected luminal narrowing of one (or more) of the splanchnic veins? | |
Always | 3 (3) |
Usually | 9 (10) |
Sometimes | 29 (31) |
Never | 52 (56) |
Main reason(s) to start therapeutic AC (multiple answers were possible) | |
To achieve vessel recanalization | 52 (56) |
To avoid complications | 81 (87) |
To prevent formation of altered venous anatomy | 31 (33) |
To prevent recurrence of SVT | 27 (29) |
To prevent another venous thromboembolism | 30 (32) |
Other reason1 | 1 (1) |
Do you screen for an underlying prothrombotic disorder? | |
Always | 2 (2) |
Usually | 12 (13) |
Sometimes | 25 (27) |
Only in patients with a history of one (or more) thrombotic events | 40 (43) |
Never | 14 (15) |
Which initial type of therapeutic AC do you prefer? | |
(Low molecular weight) heparin subcutaneous | 81 (87) |
Unfractionated heparin intravenous | 4 (4) |
Direct oral anticoagulation | 3 (3) |
Vitamin K antagonist | 4 (4) |
Platelet aggregation inhibitor | 1 (1) |
Urokinase/recombinant tissue plasminogen activator | 0 |
Which follow-up type of therapeutic AC do you prefer? | |
(Low molecular weight) heparin subcutaneous | 9 (10) |
Unfractionated heparin intravenous | 0 |
Direct oral anticoagulation | 53 (57) |
Vitamin K antagonist | 29 (31) |
Platelet aggregation inhibitor | 2 (2) |
Urokinase/recombinant tissue plasminogen activator | 0 |
Do you generally follow-up SVT after index admission? | |
Yes, clinically only | 5 (5) |
Yes, with imaging | 79 (85) |
No | 9 (10) |
After how long do you usually stop the therapeutic AC? | |
In case of achieved radiological recanalization | 13 (14) |
3 mo | 35 (38) |
6 mo | 42 (45) |
12 mo | 3 (3) |
Never | 0 |
In free text: expansion of thrombosis.
AC: Anticoagulation; SVT: Splanchnic vein thrombosis.